% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Burbulla:139516,
author = {Burbulla, Lena F and Song, Pingping and Mazzulli, Joseph R
and Zampese, Enrico and Wong, Yvette C and Jeon, Sohee and
Santos, David P and Blanz, Judith and Obermaier, Carolin D
and Strojny, Chelsee and Savas, Jeffrey N and Kiskinis,
Evangelos and Zhuang, Xiaoxi and Krüger, Rejko and
Surmeier, D James and Krainc, Dimitri},
title = {{D}opamine oxidation mediates mitochondrial and lysosomal
dysfunction in {P}arkinson's disease.},
journal = {Science / Science now},
volume = {357},
number = {6357},
issn = {0036-8075},
address = {Washington, DC},
publisher = {Assoc.60841},
reportid = {DZNE-2020-05838},
pages = {1255-1261},
year = {2017},
abstract = {Mitochondrial and lysosomal dysfunction have been
implicated in substantia nigra dopaminergic
neurodegeneration in Parkinson's disease (PD), but how these
pathways are linked in human neurons remains unclear. Here
we studied dopaminergic neurons derived from patients with
idiopathic and familial PD. We identified a time-dependent
pathological cascade beginning with mitochondrial oxidant
stress leading to oxidized dopamine accumulation and
ultimately resulting in reduced glucocerebrosidase enzymatic
activity, lysosomal dysfunction, and α-synuclein
accumulation. This toxic cascade was observed in human, but
not in mouse, PD neurons at least in part because of
species-specific differences in dopamine metabolism.
Increasing dopamine synthesis or α-synuclein amounts in
mouse midbrain neurons recapitulated pathological phenotypes
observed in human neurons. Thus, dopamine oxidation
represents an important link between mitochondrial and
lysosomal dysfunction in PD pathogenesis.},
keywords = {Animals / Antioxidants: pharmacology / Calcineurin
Inhibitors: pharmacology / Cell Line / Disease Models,
Animal / Dopamine: metabolism / Dopaminergic Neurons:
metabolism / Glucosylceramidase: deficiency / Humans /
Lysosomes: metabolism / Melanins: metabolism /
Mesencephalon: enzymology / Mesencephalon: metabolism / Mice
/ Mice, Knockout / Mitochondria: drug effects /
Mitochondria: enzymology / Mitochondria: metabolism /
Oxidation-Reduction / Oxidative Stress: drug effects /
Parkinson Disease: enzymology / Parkinson Disease: genetics
/ Parkinson Disease: metabolism / Protein Deglycase DJ-1:
genetics / Substantia Nigra: enzymology / Substantia Nigra:
metabolism / Tacrolimus: pharmacology / alpha-Synuclein:
metabolism / Antioxidants (NLM Chemicals) / Calcineurin
Inhibitors (NLM Chemicals) / Melanins (NLM Chemicals) /
alpha-Synuclein (NLM Chemicals) / neuromelanin (NLM
Chemicals) / PARK7 protein, human (NLM Chemicals) / Protein
Deglycase DJ-1 (NLM Chemicals) / Glucosylceramidase (NLM
Chemicals) / Dopamine (NLM Chemicals) / Tacrolimus (NLM
Chemicals)},
cin = {AG N.N. 3 / AG Gasser 1},
ddc = {320},
cid = {I:(DE-2719)1240015 / I:(DE-2719)1210000},
pnm = {345 - Population Studies and Genetics (POF3-345) / 344 -
Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-345 / G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28882997},
pmc = {pmc:PMC6021018},
doi = {10.1126/science.aam9080},
url = {https://pub.dzne.de/record/139516},
}